Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC)

被引：3

作者：

Noor Z.S. ^{[1
]}

Master A. ^{[1
]}

机构：

[1] David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

来源：

Current Breast Cancer Reports | 2018年 / 10卷 / 4期

关键词：

Antibody-drug conjugate; Immune checkpoint inhibition; PARP inhibitors; Targeted therapy; TNBC; Triple-negative breast cancer;

D O I：

10.1007/s12609-018-0291-x

中图分类号：

学科分类号：

摘要：

Purpose of Review: We will provide a brief update of the most recent advances in targeted therapies for triple-negative breast cancer (TNBC) to help guide the practicing oncologist faced with the dilemma of how to treat this complex disease. Recent Findings: The current standard of care remains chemotherapy, with recent data supporting the use of platinum agents and poly(ADP-ribose) polymerases (PARP) inhibitors. Immune checkpoint inhibitor trials have also shown efficacy. Summary: TNBCs are grouped together, yet there is an extraordinary amount of diversity amongst these cancers, which have distinct molecular subtypes that predict response to therapy. The use of platinum agents and PARP inhibitors is now well supported. Novel agents including checkpoint inhibitors and antibody-drug conjugates hold promising avenues for the future. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.

引用

页码：282 / 288

页数：6

共 50 条

[21] BRCA gene activity in triple-negative breast cancer (TNBC). Relevance for prognosis and therapy?
Hüttemann U.
Langer E.
Schönherr A.
Zwiefel K.
Neumann M.
Janni W.
Mohrmann S.
[J]. Der Gynäkologe, 2010, 43 (12): : 1002 - 1007
[22] Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice
Schneeweiss, Andreas
Denkert, Carsten
Fasching, Peter A.
Fremd, Carlo
Gluz, Oleg
Kolberg-Liedtke, Cornelia
Loibl, Sibylle
Lueck, Hans-Joachim
[J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (06) : 605 - 617
[23] Targeted Therapies in Triple-Negative Breast Cancer
Marme, Frederik
Schneeweiss, Andreas
[J]. BREAST CARE, 2015, 10 (03) : 159 - 166
[24] Targeted Treatment of Triple-Negative Breast Cancer
Young, Joanna A.
Tan, Antoinette R.
[J]. CANCER JOURNAL, 2021, 27 (01): : 50 - 58
[25] Targeted Therapies for Triple-Negative Breast Cancer
Tomas G. Lyons
[J]. Current Treatment Options in Oncology, 2019, 20
[26] Targeted Therapies for Triple-Negative Breast Cancer
Lyons, Tomas G.
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (11)
[27] Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Raju, V.
Yasothamani, V.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1272 - S1272
[28] Current advances in biomarkers for targeted therapy in triple-negative breast cancer
Fleisher, Brett
Clarke, Charlotte
Ait-Oudhia, Sihem
[J]. BREAST CANCER-TARGETS AND THERAPY, 2016, 8 : 183 - 197
[29] Translating the Molecular Message of Triple-Negative Breast Cancer into Targeted Therapy
Vidula, Neelima
Rugo, Hope S.
[J]. CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1511 - 1513
[30] Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer
Kumari, Mamta
Krishnamurthy, Praveen Thaggikuppe
Sola, Piyong
[J]. CURRENT CANCER DRUG TARGETS, 2020, 20 (08) : 559 - 572

← 1 2 3 4 5 →